Agios Pharmaceuticals (AGIO) Scheduled to Post Quarterly Earnings on Thursday

Agios Pharmaceuticals (NASDAQ:AGIO) is scheduled to be announcing its earnings results before the market opens on Thursday, May 2nd. Analysts expect the company to announce earnings of ($1.63) per share for the quarter. Individual interested in participating in the company’s earnings conference call can do so using this link.

Agios Pharmaceuticals (NASDAQ:AGIO) last issued its quarterly earnings results on Thursday, February 15th. The biopharmaceutical company reported ($1.72) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.64) by ($0.08). Agios Pharmaceuticals had a negative net margin of 1,312.64% and a negative return on equity of 38.08%. The business had revenue of $7.10 million during the quarter, compared to analyst estimates of $7.80 million. During the same quarter in the previous year, the firm posted $0.67 earnings per share. The firm’s quarterly revenue was up 65.1% on a year-over-year basis. On average, analysts expect Agios Pharmaceuticals to post $-5 EPS for the current fiscal year and $-6 EPS for the next fiscal year.

Agios Pharmaceuticals Price Performance

Agios Pharmaceuticals stock opened at $31.67 on Thursday. The company has a market cap of $1.78 billion, a price-to-earnings ratio of -5.00 and a beta of 0.83. The firm has a 50-day moving average of $29.80 and a 200-day moving average of $25.13. Agios Pharmaceuticals has a one year low of $19.80 and a one year high of $35.50.

Insider Activity

In related news, Director Jacqualyn A. Fouse sold 7,791 shares of the business’s stock in a transaction that occurred on Wednesday, April 10th. The stock was sold at an average price of $27.55, for a total transaction of $214,642.05. Following the transaction, the director now directly owns 137,396 shares of the company’s stock, valued at approximately $3,785,259.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Agios Pharmaceuticals news, Director Jacqualyn A. Fouse sold 7,791 shares of Agios Pharmaceuticals stock in a transaction on Wednesday, April 10th. The shares were sold at an average price of $27.55, for a total transaction of $214,642.05. Following the completion of the transaction, the director now directly owns 137,396 shares of the company’s stock, valued at $3,785,259.80. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider James William Burns sold 2,642 shares of the stock in a transaction dated Tuesday, March 5th. The shares were sold at an average price of $32.57, for a total transaction of $86,049.94. Following the completion of the transaction, the insider now directly owns 34,518 shares in the company, valued at $1,124,251.26. The disclosure for this sale can be found here. Insiders sold a total of 16,035 shares of company stock valued at $475,277 over the last three months. Insiders own 4.24% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on AGIO. Royal Bank of Canada lowered their price target on Agios Pharmaceuticals from $43.00 to $42.00 and set an “outperform” rating on the stock in a research report on Friday, February 16th. Cantor Fitzgerald reissued an “overweight” rating on shares of Agios Pharmaceuticals in a research note on Tuesday, April 9th. Finally, JPMorgan Chase & Co. dropped their price target on shares of Agios Pharmaceuticals from $31.00 to $30.00 and set a “neutral” rating on the stock in a research report on Friday, February 23rd. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and two have given a buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $33.50.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.